NOW APPROVED FOR
MULTIPLE INDICATIONS
Find out more at
hcp.eliquis.com
ELIQUIS® (apixaban) is
• ndicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular
i
atrial fibrillation
• ewly indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary
n
embolism (PE), in patients who have undergone hip replacement surgery
• ewly indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary
n
embolism (PE), in patients who have undergone knee replacement surgery
SELECTED IMPORTANT SAFETY INFORMATION
WARNINGS: (A) DISCONTINUING ELIQUIS IN PATIENTS WITH NONVALVULAR ATRIAL
FIBRILLATION WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK
OF STROKE, (B) SPINAL/EPIDURAL HEMATOMA
(A) DISCONTINUING ELIQUIS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE:
Discontinuing ELIQUIS places patients at an increased risk of thrombotic events. An increased
rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients
with nonvalvular atrial fibrillation. If anticoagulation with ELIQUIS must be discontinued for
a reason other than pathological bleeding, coverage with another anticoagulant should be
strongly considered.
(B) SPINAL/EPIDURAL HEMATOMA: ELIQUIS use in patients undergoing spinal epidural
anesthesia or spinal puncture increases the risk of epidural or spinal hematoma which may
cause long-term or permanent paralysis. Monitor patients frequently for signs and symptoms
of neurologic impairment and if observed, treat urgently. Consider the benefits and risks
before neuraxial intervention in patients who are or who need to be anticoagulated.
See adjacent pages for complete Boxed WARNINGS.
Please see Important Safety Information and Brief Summary of Full Prescribing Information,
including Boxed WARNINGS, on following pages.